My Biggest Investing Regret in 2025 Was Buying This Stock

Canopy Growth is a cautionary reminder to buy businesses, not headlines, especially in hype-driven sectors like cannabis.

| More on:
Pot stocks are a riskier investment

Image source: Getty Images

Key Points

  • WEED still has recognizable brands and occasional policy-fueled rallies, but timelines and follow-through often disappoint.
  • Recent results showed modest revenue growth and better cost control, yet profitability remains elusive.
  • The big risks are ongoing losses, dilution if financing returns, and slow-moving U.S. regulatory change.

Regret shows up when you replay 2025 with today’s prices, but the useful question stays simple: Did you buy a business or did you buy a story? Regret can teach you more than wins if you let it right now. High rates, headline swings, and quick “policy pivot” rumours made it easy to chase momentum and call it conviction. When you look back, separate bad process from bad luck. Write down what you thought would happen, what had to be true, and how long you planned to wait. Then check whether you followed your own rules on position size, diversification, and risk. Do you need an example? Let’s look at mine.

WEED

Yep, I invested in Canopy Growth (TSX:WEED) back in the day and certainly got some wins. It sits near the centre of Canada’s cannabis boom-and-bust story. The cannabis stock sells marijuana in Canada across adult-use and medical channels, and it also sells vaporizers through Storz & Bickel. It brands its products with names many investors recognize, like Tweed and 7ACRES. The stock still attracts attention as it feels like a “one headline away” name, for better or worse.

Over the last year, Canopy’s news flow looked like a mix of hope and hard reality. Traders chased U.S. policy headlines, especially the push to move marijuana to a less restrictive federal schedule, as that idea can change taxes and financing for the industry. The headlines sparked sharp moves, but the follow-through stayed uncertain, and investors kept pricing in delays. That gap between hype and timelines punished anyone who bought the pop and forgot the calendar.

Canopy also kept trying to reshape its balance sheet and its path into the United States. In January 2026, it announced recapitalization transactions and plans to refinance and extend maturities, with proceeds aimed at paying down existing secured debt and funding general corporate needs. That sort of move can buy time, but it also reminds you that WEED stock still needs financial engineering alongside operational improvement.

Looking at earnings

Now for the numbers that mattered most. In its second quarter of fiscal 2026, WEED stock reported consolidated net revenue of $67 million, up 6% year over year. It generated cannabis net revenue of $51 million, with $24 million from Canadian adult-use and $22 million from Canadian medical. The company also reported $298 million of cash and cash equivalents, and it said that cash exceeded debt balances by about $70 million at quarter’s end.

Those results showed real progress in a few places. Canopy cut selling, general, and administrative expenses by 13% year over year, and it said it captured $21 million of annualized savings since Mar. 1, 2025. It also narrowed its adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) loss to $3 million from $6 million a year earlier. Investors should like that direction, as cost control can create breathing room when pricing pressure hits, and consumers trade down.

However, valuation tells a harsher story, and it explains a lot of the regret. On recent quotes, WEED stock traded around $1.50 per share with a market cap near $602 million, and it showed a deeply negative trailing earnings per share of $2.67. The stock also sat way down from 52-week highs, down 48% at writing, which signals how quickly sentiment can flip in this space. Even a decent quarter can’t fix a broken long-term chart on its own.

Bottom line

Looking ahead, WEED stock’s bull case needs more than a single catalyst. It needs sustained share gains in Canada, continued expense discipline, and a clearer route to value from its U.S. interests, including brands like Wana Brands and Jetty Extracts under the Canopy USA umbrella. The bear case still looks familiar: ongoing losses, dilution risk if capital needs return, and regulatory timelines that move at political speed, not market speed. That’s why I decided to cut my losses into something more stable.

For today’s investor, set triggers. A string of quarters with shrinking losses, cash strength, and guidance you can trust. If a U.S. policy shift arrives, assume volatility, not certainty. Decide where you take profits or cut losses, then stick to it.

Fool contributor Amy Legate-Wolfe has positions in Canopy Growth. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

More on Cannabis Stocks

Yellow caution tape attached to traffic cone
Cannabis Stocks

2 Popular Stocks That Could Wipe Out a $100,000 Nest Egg

Aurora Cannabis (TSX:ACB) is one stock that could wipe out your nest egg.

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Here’s Why I Wouldn’t Touch Canopy Growth Stock With a 10-Foot Pole

Down almost 99% from all-time highs, Canopy Growth is a beaten-down cannabis stock that remains a high-risk investment in 2026.

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

2 Stocks That Could Turn $100,000 Into $0 Faster Than You Think

Canopy Growth and Plug Power are two unprofitable stocks that remain high-risk investments for shareholders in 2026.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Will Canopy Growth Keep the Losing Streak Going in 2026?

Canopy Growth Corp (TSX:WEED) was one of the market's biggest losers in 2025.

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

TFSA Investors: An Undervalued Cannabis Stock You Can Buy for $500 Right Now

Down almost 70% from all-time highs, Curaleaf is a TSX cannabis stock that trades at an attractive valuation in December…

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Can Canopy Growth Stock Finally Recover in 2026, as Donald Trump Might Ease Cannabis Restrictions?

Down over 99% from all-time highs, Canopy Growth stock might recover in 2026 if the Trump administration reclassifies cannabis products.

Read more »

Researcher works in hemp field
Cannabis Stocks

Forget Tilray and Buy This Cannabis Stock if the U.S. Reclassifies Marijuana in 2026

While Tilray stock gained over 40% on Friday, this cannabis company is a better buy if the U.S. reclassifies marijuana…

Read more »

A cannabis plant grows.
Cannabis Stocks

Aurora Cannabis Surged 21% on Possible Cannabis Reclassification in the U.S. Is ACB Stock Finally a Good Buy?

Down almost 99% from all-time highs, Aurora Cannabis is a beaten-down marijuana stock that offers upside potential in December 2025.

Read more »